shold of 35 ml/m2 in risk stratification after AVR. BACKGROUND Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail. Selleckchem GW 501516…[Read more]